Coeptis Therapeutics Holdings, Inc. (COEP)
NASDAQ: COEP · Real-Time Price · USD
0.142
-0.003 (-2.08%)
Dec 20, 2024, 4:00 PM EST - Market closed
COEP Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
7
Market Cap
5.82M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
IM Cannabis | 38.04M |
Ontrak | 11.24M |
Tenon Medical | 3.32M |
Intelligent Bio Solutions | 3.19M |
Mangoceuticals | 755.00K |
COEP News
- 10 days ago - Coeptis Therapeutics Unveils New Technology Division: Coeptis Technologies - PRNewsWire
- 19 days ago - Coeptis Therapeutics Executes Binding Letter of Intent to Acquire Ai-powered Marketing Solutions for Biotech, Pharmaceutical and Other Industries - PRNewsWire
- 6 weeks ago - Coeptis Therapeutics Announces Phase 1 Data on DVX201 for COVID-19 Treatment Has Been Accepted for Publication in Molecular Therapy Methods and Clinical Development - PRNewsWire
- 2 months ago - Coeptis Therapeutics Expands License Agreement with Deverra to Include Pandemic Preparedness, and Emergency Use - PRNewsWire
- 2 months ago - Coeptis Therapeutics' Chief Scientific and Medical Officer to Present at Upcoming Fall Conferences, Highlighting Progress in Universal Cell Therapy - PRNewsWire
- 3 months ago - Coeptis Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing - PRNewsWire
- 3 months ago - Coeptis Therapeutics Chief Executive Officer, Dave Mehalick, Updates and Outlines Strategic Vision in Letter to Shareholders - PRNewsWire
- 6 months ago - Coeptis Therapeutics Closes on $4.3 Million of Series A Preferred Offering - PRNewsWire